FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149676962> ?p ?o ?g. }

• W3149676962 endingPage "1284" @default.
• W3149676962 startingPage "1277" @default.
• W3149676962 abstract "Objective: To assess the efficacy and safety of the sodium–glucose cotransporter 2 inhibitor ertugliflozin across racial groups in patients with type 2 diabetes mellitus (T2DM).Methods: Pooled analysis of data from randomized, double-blind studies in the ertugliflozin phase III development program. Seven placebo- and comparator-controlled studies were used to assess safety (N = 4859) and three placebo-controlled studies were used to assess efficacy (N = 1544). Least-squares (LS) mean change from baseline was calculated for glycated hemoglobin (HbA1c), body weight and systolic blood pressure (SBP). Safety evaluation included overall and prespecified adverse events (AEs).Results: At Week 26, ertugliflozin provided a greater reduction in HbA1c, body weight and SBP versus placebo in all racial subgroups. The placebo-adjusted LS mean change (95% confidence interval) from baseline in HbA1c was −0.8% (−1.0, −0.7) and −1.0% (−1.1, −0.8) with ertugliflozin 5 mg and 15 mg, respectively, in the White subgroup, −0.7% (−1.2, −0.2) and −0.8% (−1.3, −0.3) in the Black subgroup, and −0.8% (−1.1, −0.5) and −1.0% (−1.3, −0.8) in the Asian subgroup. The incidences of overall AEs, serious AEs and AEs leading to discontinuation from study medication were similar between the ertugliflozin 5 mg, 15 mg and non-ertugliflozin groups within each racial subgroup. The incidence of female genital mycotic infection (GMI) was higher with ertugliflozin than non-ertugliflozin across all racial subgroups. The incidence of male GMI was higher with ertugliflozin than non-ertugliflozin in the White sub-group; however, there were few male GMI events in the non-White subgroups.Conclusions: In patients with T2DM, treatment with ertugliflozin improved HbA1c, body weight and SBP across all racial subgroups. Ertugliflozin had a generally similar safety profile across racial subgroups and was generally well tolerated. Clinicaltrials.gov identifiers: NCT01986855, NCT01999218, NCT01958671, NCT02099110, NCT02036515, NCT02033889, and NCT02226003." @default.
• W3149676962 created "2021-04-13" @default.
• W3149676962 creator A5000786302 @default.
• W3149676962 creator A5016580311 @default.
• W3149676962 creator A5026935251 @default.
• W3149676962 creator A5069139545 @default.
• W3149676962 creator A5075548249 @default.
• W3149676962 creator A5078590370 @default.
• W3149676962 creator A5079194052 @default.
• W3149676962 creator A5079232498 @default.
• W3149676962 creator A5084634888 @default.
• W3149676962 creator A5087916852 @default.
• W3149676962 date "2020-05-13" @default.
• W3149676962 modified "2023-10-17" @default.
• W3149676962 title "Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus" @default.
• W3149676962 cites W2096636509 @default.
• W3149676962 cites W2106637089 @default.
• W3149676962 cites W2112002662 @default.
• W3149676962 cites W2113551073 @default.
• W3149676962 cites W2121922368 @default.
• W3149676962 cites W2492672367 @default.
• W3149676962 cites W2581807473 @default.
• W3149676962 cites W2736121628 @default.
• W3149676962 cites W2752384709 @default.
• W3149676962 cites W2754339077 @default.
• W3149676962 cites W2766278264 @default.
• W3149676962 cites W2769581384 @default.
• W3149676962 cites W2776047972 @default.
• W3149676962 cites W2777413433 @default.
• W3149676962 cites W2783572748 @default.
• W3149676962 cites W2789976029 @default.
• W3149676962 cites W2804441505 @default.
• W3149676962 cites W2890465901 @default.
• W3149676962 cites W2891073947 @default.
• W3149676962 cites W2901142459 @default.
• W3149676962 cites W2926211709 @default.
• W3149676962 cites W2944815545 @default.
• W3149676962 cites W2992649039 @default.
• W3149676962 cites W4242618933 @default.
• W3149676962 doi "https://doi.org/10.1080/03007995.2020.1760228" @default.
• W3149676962 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32324082" @default.
• W3149676962 hasPublicationYear "2020" @default.
• W3149676962 type Work @default.
• W3149676962 sameAs 3149676962 @default.
• W3149676962 citedByCount "6" @default.
• W3149676962 countsByYear W31496769622019 @default.
• W3149676962 countsByYear W31496769622020 @default.
• W3149676962 countsByYear W31496769622021 @default.
• W3149676962 countsByYear W31496769622022 @default.
• W3149676962 countsByYear W31496769622023 @default.
• W3149676962 crossrefType "journal-article" @default.
• W3149676962 hasAuthorship W3149676962A5000786302 @default.
• W3149676962 hasAuthorship W3149676962A5016580311 @default.
• W3149676962 hasAuthorship W3149676962A5026935251 @default.
• W3149676962 hasAuthorship W3149676962A5069139545 @default.
• W3149676962 hasAuthorship W3149676962A5075548249 @default.
• W3149676962 hasAuthorship W3149676962A5078590370 @default.
• W3149676962 hasAuthorship W3149676962A5079194052 @default.
• W3149676962 hasAuthorship W3149676962A5079232498 @default.
• W3149676962 hasAuthorship W3149676962A5084634888 @default.
• W3149676962 hasAuthorship W3149676962A5087916852 @default.
• W3149676962 hasBestOaLocation W31496769621 @default.
• W3149676962 hasConcept C120665830 @default.
• W3149676962 hasConcept C121332964 @default.
• W3149676962 hasConcept C126322002 @default.
• W3149676962 hasConcept C134018914 @default.
• W3149676962 hasConcept C142724271 @default.
• W3149676962 hasConcept C187960798 @default.
• W3149676962 hasConcept C197934379 @default.
• W3149676962 hasConcept C204787440 @default.
• W3149676962 hasConcept C27081682 @default.
• W3149676962 hasConcept C2777180221 @default.
• W3149676962 hasConcept C2777538456 @default.
• W3149676962 hasConcept C44249647 @default.
• W3149676962 hasConcept C555293320 @default.
• W3149676962 hasConcept C61511704 @default.
• W3149676962 hasConcept C71924100 @default.
• W3149676962 hasConcept C90924648 @default.
• W3149676962 hasConceptScore W3149676962C120665830 @default.
• W3149676962 hasConceptScore W3149676962C121332964 @default.
• W3149676962 hasConceptScore W3149676962C126322002 @default.
• W3149676962 hasConceptScore W3149676962C134018914 @default.
• W3149676962 hasConceptScore W3149676962C142724271 @default.
• W3149676962 hasConceptScore W3149676962C187960798 @default.
• W3149676962 hasConceptScore W3149676962C197934379 @default.
• W3149676962 hasConceptScore W3149676962C204787440 @default.
• W3149676962 hasConceptScore W3149676962C27081682 @default.
• W3149676962 hasConceptScore W3149676962C2777180221 @default.
• W3149676962 hasConceptScore W3149676962C2777538456 @default.
• W3149676962 hasConceptScore W3149676962C44249647 @default.
• W3149676962 hasConceptScore W3149676962C555293320 @default.
• W3149676962 hasConceptScore W3149676962C61511704 @default.
• W3149676962 hasConceptScore W3149676962C71924100 @default.
• W3149676962 hasConceptScore W3149676962C90924648 @default.
• W3149676962 hasIssue "8" @default.
• W3149676962 hasLocation W31496769621 @default.
• W3149676962 hasOpenAccess W3149676962 @default.
• W3149676962 hasPrimaryLocation W31496769621 @default.

• next